Helen Steers, Partner at Pantheon and Manager of Pantheon International Plc (PIP), addresses some of the common myths surrounding private equity.
By killing so-called zombie cells which accelerate the ageing process, drugs called senolytics promise to keep us younger and fitter for longer.
In this weekly update, Longevity.Technology Editor-in-Chief Phil Newman keeps us up to date with all the latest developments in longevity.
In this weekly update, Longevity.Technology Editor-in-Chief Phil Newman keeps us up to date with all the latest developments in longevity.
Michael Corcoran and James Lawford Davies of Hill Dickinson discuss the firm’s participation in Longevity Week and the longevity sector in general.
In this weekly update, Longevity.Technology Editor-in-Chief Phil Newman keeps us up to date with all the latest developments in longevity.
In this weekly update, Longevity.Technology Editor-in-Chief Phil Newman keeps us up to date with all the latest developments in longevity.
In this weekly update, longevity.technology Editor in Chief Phil Newman keeps us up to date with all the latest development in the longevity space.
It is too early to be overly confident, but we are gradually building confidence in the outlook for the market, writes Jamie Ross of Henderson EuroTrust.
Ben Lofthouse, Head of Global Equity Income, and Jane Shoemake, Investment Director, assess the outlook for global dividends in the wake of the COVID-19 pandemic.
